From Hydrogen Dreams to Leveraged ETFs: The Chaos in Wall Street's Leftovers

This is a bizarre, fragmented market, and if you look at the odd bag of leftover stocks catching attention this week, you'll see why. We have hydrogen dreams, overpriced shoes, cell therapies, and single-stock leveraged ETFs all thrown into one chaotic bucket. Let's see who is actually making money and who is just pretending.

Plug Power (PLUG.US) is still trying to convince us that the hydrogen highway is real. The stock saw a decent bounce recently, and they managed to shrink their gross margin bleeding to near break-even in Q2 2026, pushing their full-year revenue growth guidance to 15%. Good luck with that. Until they stop burning cash like it's going out of style, it's just another science project.

Deckers Outdoor (DECK.US) crossed the USD 1.02 billion quarterly revenue mark for the first time in Q1 fiscal 2027, thanks to UGGs and HOKAs being everywhere. But Wall Street threw a fit over tariff pressures and the margin outlook, sending the stock down this month. Why aren't you moving faster to diversify your supply chain? They raised their EPS guidance, but in this consumer environment, you can't afford to slip.

Legend Biotech (LEGN.US) just swapped CEOs, bringing in Ingrid Zhang to navigate the fierce competition for Carvykti. But make no mistake, their multiple myeloma therapy brought in roughly USD 657 million in Q2 2026, up 50% year-over-year. That's real money, folks. This is a solid business, not a meme.

Velo3D (VELO.US) printed a 52.3% revenue jump in Q2 2026, hitting USD 20.7 million. They are selling 3D metal printers to the defense and space sectors, which is cool, but they are still a tiny player trying to prove they belong in the big leagues. Opening a massive new facility in Livermore is a flex, but let's see if the orders follow.

Illumina (ILMN.US) is finally showing signs of life. They reported USD 1.16 billion in Q2 2026 revenue, up 9.5%. After a disastrous couple of years, they flipped a massive loss into a USD 366 million net income in the first half of 2026. This is what a turnaround looks like when adults are back in the room.

Then we have the leverage junkies. Leverage Shares 2x Long GEMI (GEMG.US) and Defiance Daily Target 2X Long HIMS ETF (HIMZ.US) are out here offering 200% daily exposure to single stocks. This is stupid and here's why: these are pure gambling vehicles for retail traders who don't understand decay. If you are holding these for more than a day, you deserve what happens to your portfolio.

And let's not forget the obscure corners of the market like AAOZ (AAOZ.US), AXTQ (AXTQ.US), and PENG (PENG.US). Whether they are niche products or forgotten micro-caps, they represent the absolute long tail of Wall Street. Unless you have a very specific reason to be looking at them, just skip them.

This odd mix proves how disjointed the market is right now. Stick your money where the actual revenue is.

This article does not constitute investment advice.